VKTX · PEAD ↓ 84

Viking Therapeutics reported Q2 2026 results on 2026-07-22; consensus EPS was -$1.21 (actual not yet in our feed).

Print-day reaction was -1.7% versus the prior close of $37.95, as the stock slipped to $37.31 on the event date. The overnight gap to the T+1 open added a further -1.8%, signalling continued selling pressure with no after-hours recovery. Over the subsequent two trading days the price drifted an additional -1.5%, confirming a sustained downward continuation with no mean-reversion. Cumulative abnormal return of -6.9% versus SPY.US firmly places this in PEAD short territory; per the documented drift pattern, the read holds through 2026-10-19.